Know Cancer

forgot password

Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme

Phase 2
18 Years
Open (Enrolling)
Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme

Thank you

Trial Information

Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme

Inclusion Criteria


- Histologically confirmed diagnosis of recurrent/progressive GBM presenting in first,
second, or third relapse (progression following anti-cancer therapy other than

- Bidimensionally measurable recurrent or residual primary disease on contrast-enhanced



• 18 and over


- ANC ≥ 1,500/mL

- Platelets ≥ 100,000/mL

- Hemoglobin ≥ 9.0g/dL


- AST and ALT ≤ 1.5 x ULN

- Bilirubin ≤ 1.5 x ULN


• INR < 1.5 or PT within normal limits; and PTT within normal limits


Creatinine ≤ 1.5 x ULN; Urine protein/creatinine ratio ≤ 1


- 2-dimensional echocardiogram or cardiac multigated acquisition (MUGA) scan
demonstrating left ventricular ejection fraction within the institutional normal

- No coronary artery bypass graft, angioplasty, vascular stenting, myocardial
infarction, unstable angina, congestive heart failure within the preceding 12 months.

- No thrombotic or embolic cerebrovascular accident, including transient ischemic
attacks within the past 12 months and no conditions that would not permit the safe
discontinuation of specified anti-platelet medications

- No intraparenchymal CNS hemorrhage, except for Grade 1 intraparenchymal hemorrhage in
the immediate post-operative period or Grade 1 intraparenchymal hemorrhage that has
been stable or improved


• Not known to have human immunodeficiency virus infection (HIV) or active hepatitis B or
C virus infection


- Negative pregnancy test within 72 hours prior to drug administration

- Not pregnant or breast feeding

- Fertile patients must agree to use effective methods of birth control and must agree
to do so until at least 4 weeks after the last dose of drug administration

- No serious non-healing wound, ulcer or bone fracture or recent significant traumatic
injury (within 4 weeks)

- Have ability to understand and sign an informed consent document

- Be willing and able to comply with scheduled visits, treatment plan, laboratory
tests, and other study procedures

- No other malignancy within the past 3 years, except for basal cell skin cancer,
cervical carcinoma in situ, or other primary malignancy that is not currently
clinically significant or does not require active intervention

- No prior grade 3 or greater toxicity to irinotecan

- No other severe, acute, or chronic medical or psychiatric condition or laboratory
abnormality that could increase the risks associated with study participation or
study drug administration or could interfere with the interpretation of the study
results and would make the patient inappropriate for study entry


Biologic therapy:

- See Disease Characteristics

- At least 4 weeks between prior biological or immunotherapy and recovered


- See Disease Characteristics

- At least 4 weeks since prior chemotherapy and recovered (6 weeks for nitrosoureas),
unless there is unequivocal evidence of tumor progression


• At least 12 weeks from completion of standard, daily radiotherapy and recovered, unless
any of the following occurs:

- New area of enhancement on MRI that is outside the radiotherapy field

- Biopsy-proven recurrent tumor

- Radiographic evidence of progressive tumor on 2 consecutive scans taken ≥ 4 weeks


- At least 4 weeks since major surgery, open biopsy or significant traumatic injury and

- At least 1 week since other prior biopsy


- Not concurrently enrolled in another therapeutic clinical trial involving ongoing

- No prior treatment with VEGF or VEGFR inhibitors or vascular targeting/disrupting

- No prior CT-322 therapy

- No prior failure of irinotecan therapy

- No prior treatment with stereotactic radiosurgery, brachytherapy, or a surgically
created resection cavity to support other anatomically localized therapies

- No severe or uncontrolled medical disease (uncontrolled diabetes, hypertension,
serious infection > CTCAE grade 2, significant bleeding or platelet dysfunction,
gastrointestinal bleed)

Type of Study:


Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerability of CT-322 when administered alone or in combination with irinotecan hydrochloride (Part 1)

Outcome Time Frame:

15 ± 5 days post the last dose of study drug

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

October 2007

Completion Date:

December 2011

Related Keywords:

  • Brain and Central Nervous System Tumors
  • Recurrent Glioblastoma Multiforme
  • Glioblastoma
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms



MD Anderson Cancer Center Houston, Texas  77030-4096
Rhode Island Hospital Providence, Rhode Island  02903
Duke University Medical Center Durham, North Carolina  27710
SUNY Upstate Medical University Syracuse, New York  13210
Henry Ford Health System Detroit, Michigan  48202
Dana Farber Cancer Institute Boston, Massachusetts  02115
University of Wisconsin Hospital Madison, Wisconsin  53792
University of Kentucky Lexington, Kentucky  40536-0098
University of California, San Diego La Jolla, California  92037-1709
University of Virgina Charlottesville, Virginia  22908